News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Galapagos informed about the initiation of a clinical trial to evaluate potential pharmacokinetic interactions of GLPG4716
21 July 2021
OncoArendi executes the strategy for 2021-2025 in the area of R&D platform for developing small molecules modulating RNA function
16 June 2021
OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis
5 November 2020
American Journal of Medicinal Chemistry distinguishes OncoArendi publication on OATD-01
21 October 2020
OncoArendi Therapeutics expands the therapeutic potential of its Chitinase Platform
13 October 2020
OncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients
11 September 2020